Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 137.14 Billion KRW | -15.7% |
| 2022 | 162.67 Billion KRW | -6.58% |
| 2021 | 174.13 Billion KRW | -21.9% |
| 2020 | 222.96 Billion KRW | 40.36% |
| 2019 | 158.84 Billion KRW | 15.3% |
| 2018 | 137.77 Billion KRW | -25.29% |
| 2017 | 184.41 Billion KRW | 4.62% |
| 2016 | 176.27 Billion KRW | 96.9% |
| 2015 | 89.52 Billion KRW | 155.82% |
| 2014 | 34.99 Billion KRW | 143.12% |
| 2013 | 14.39 Billion KRW | -6.18% |
| 2012 | 15.34 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 138.74 Billion KRW | 1.17% |
| 2024 Q2 | 136.19 Billion KRW | -1.84% |
| 2023 Q4 | 137.14 Billion KRW | 4.29% |
| 2023 FY | 137.14 Billion KRW | -15.7% |
| 2023 Q1 | 137.1 Billion KRW | -15.72% |
| 2023 Q2 | 119.25 Billion KRW | -13.01% |
| 2023 Q3 | 131.49 Billion KRW | 10.26% |
| 2022 FY | 162.67 Billion KRW | -6.58% |
| 2022 Q2 | 163.13 Billion KRW | 0.18% |
| 2022 Q1 | 162.83 Billion KRW | -6.49% |
| 2022 Q4 | 162.67 Billion KRW | -3.14% |
| 2022 Q3 | 167.94 Billion KRW | 2.95% |
| 2021 Q3 | 177.35 Billion KRW | -18.8% |
| 2021 Q4 | 174.13 Billion KRW | -1.82% |
| 2021 Q2 | 218.41 Billion KRW | -0.97% |
| 2021 Q1 | 220.54 Billion KRW | -1.08% |
| 2021 FY | 174.13 Billion KRW | -21.9% |
| 2020 Q4 | 222.96 Billion KRW | 2.83% |
| 2020 FY | 222.96 Billion KRW | 40.36% |
| 2020 Q3 | 216.83 Billion KRW | -4.12% |
| 2020 Q2 | 226.15 Billion KRW | 9.83% |
| 2020 Q1 | 205.9 Billion KRW | 29.62% |
| 2019 Q1 | 133.88 Billion KRW | 20.82% |
| 2019 Q2 | 141.3 Billion KRW | 5.54% |
| 2019 Q3 | 150.07 Billion KRW | 6.2% |
| 2019 Q4 | 158.84 Billion KRW | 5.85% |
| 2019 FY | 158.84 Billion KRW | 15.3% |
| 2018 FY | 137.77 Billion KRW | -25.29% |
| 2018 Q4 | 110.81 Billion KRW | -6.13% |
| 2018 Q3 | 118.05 Billion KRW | 6.1% |
| 2018 Q2 | 111.26 Billion KRW | -30.7% |
| 2018 Q1 | 160.55 Billion KRW | -12.94% |
| 2017 Q2 | 181.2 Billion KRW | 1.84% |
| 2017 Q1 | 177.92 Billion KRW | 0.89% |
| 2017 FY | 184.41 Billion KRW | 4.62% |
| 2017 Q4 | 184.41 Billion KRW | 1.81% |
| 2017 Q3 | 181.14 Billion KRW | -0.03% |
| 2016 Q3 | 162.22 Billion KRW | 193.64% |
| 2016 Q1 | 54.21 Billion KRW | 14.06% |
| 2016 FY | 176.27 Billion KRW | 96.9% |
| 2016 Q2 | 55.24 Billion KRW | 1.89% |
| 2016 Q4 | 176.35 Billion KRW | 8.71% |
| 2015 FY | 89.52 Billion KRW | 155.82% |
| 2015 Q4 | 47.53 Billion KRW | -35.74% |
| 2015 Q3 | 73.96 Billion KRW | -5.16% |
| 2015 Q2 | 77.99 Billion KRW | 114.48% |
| 2015 Q1 | 36.36 Billion KRW | 3.91% |
| 2014 Q1 | 31.65 Billion KRW | 119.89% |
| 2014 Q3 | 36.21 Billion KRW | 58.62% |
| 2014 Q4 | 34.99 Billion KRW | -3.36% |
| 2014 FY | 34.99 Billion KRW | 143.12% |
| 2014 Q2 | 22.82 Billion KRW | -27.87% |
| 2013 Q3 | 13.46 Billion KRW | -7.91% |
| 2013 Q1 | 17.71 Billion KRW | 15.45% |
| 2013 FY | 14.39 Billion KRW | -6.18% |
| 2013 Q2 | 14.62 Billion KRW | -17.47% |
| 2013 Q4 | 14.39 Billion KRW | 6.91% |
| 2012 FY | 15.34 Billion KRW | 0.0% |
| 2012 Q4 | 15.34 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 19.079% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -7193.303% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -81.197% |
| Bioneer Corporation | 80.61 Billion KRW | -70.127% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -586.158% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | -1.035% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -40.193% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -86.44% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 87.174% |
| Peptron, Inc. | 16.36 Billion KRW | -737.808% |
| Amicogen, Inc. | 248.12 Billion KRW | 44.729% |
| Genexine, Inc. | 79.68 Billion KRW | -72.108% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -368.44% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -232.213% |
| ALTEOGEN Inc. | 108.25 Billion KRW | -26.679% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -87.641% |
| SillaJen, Inc. | 19.4 Billion KRW | -606.876% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 23.424% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -161.274% |
| Genomictree Inc. | 7.81 Billion KRW | -1655.452% |
| MedPacto, Inc. | 9.56 Billion KRW | -1333.666% |
| D&D Pharmatech | 23.98 Billion KRW | -471.76% |
| EASY BIO,Inc. | 105.86 Billion KRW | -29.538% |
| GI Innovation, Inc. | 9.63 Billion KRW | -1323.18% |